Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Relapsed and Refractory Indolent Lymphomas
NCT00005786Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2001
- Primary completion
- Nov 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in lymphoma, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) and 1 more, sponsored by National Cancer Institute. Primary endpoints: Safety and toxicity profile up to 2 years and Incidence of complete and partial response up to 2 years. Started Jan 2001; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
lymphomachronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00005786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005786.